MYX mayne pharma group limited

Ann: Change in substantial holding, page-15

  1. 335 Posts.
    lightbulb Created with Sketch. 266
    As far as revenue goes, you may be missing any attribution to growth in 2HFY23.
    Sure, 1HFY23 revenue was A$10.44 for about 110,000 cycles so that's an achieved price of $95/cycle.
    For 2HFY23 the CEO has already stated that cycles in December 2022 were 20,000 and by February cycles were growing by 5%/week, so if one was to assume those figures for the remainder of the year, that's about 240,000 cycles for the second half and possibly A$20-25M for 2HFY23.
    So my figures for FY23 are closer to A$35 than $20.

    My projection on this basis, is that we will be exiting June with a weekly sales cycle of between 14,000 to 20,000 and if no further growth occurred in FY2024 we will have sales of between A$70 and A$100 m for FY 24. That's a profitable product, sure not the US$200M projected. With modest 2% weekly growth in FY2024 we are looking at closer to A$140M.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.03
Change
-0.170(3.27%)
Mkt cap ! $408.6M
Open High Low Value Volume
$5.20 $5.21 $5.03 $2.804M 555.6K

Buyers (Bids)

No. Vol. Price($)
2 14654 $5.03
 

Sellers (Offers)

Price($) Vol. No.
$5.14 3111 2
View Market Depth
Last trade - 16.10pm 20/06/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.